Free Trial
→ Banks aren’t ready for this altcoin—are you? (From Crypto 101 Media) (Ad)

20 Stocks Wall Street Analysts Love the Most - 15 of 20

Slide 15
Back to 14
Continue to 16
 
Back to 14
Continue to 16
 

BioMarin Pharmaceutical (NASDAQ:BMRN)

Consensus Rating
Moderate Buy
Rating Score
2.7
Ratings Breakdown
17 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$93.45 (66.2% Upside)

About BioMarin Pharmaceutical

BioMarin Pharmaceutical logoBioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. More about BioMarin Pharmaceutical
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
5/5/2025The Goldman Sachs GroupLower Price TargetBuy ➝ Buy$124.00 ➝ $104.00
5/2/2025CitigroupLower Price TargetNeutral ➝ Neutral$82.00 ➝ $78.00
2/24/2025OppenheimerUpgradeMarket Perform ➝ Outperform$98.00
2/20/2025WedbushReiterated RatingOutperform$94.00
2/20/2025CitigroupBoost Price TargetNeutral ➝ Neutral$81.00 ➝ $82.00
2/20/2025ScotiabankBoost Price TargetSector Perform ➝ Sector Perform$78.00 ➝ $80.00
2/20/2025Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$70.00 ➝ $70.00
2/20/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00
2/20/2025UBS GroupBoost Price TargetBuy ➝ Buy$109.00 ➝ $113.00
2/20/2025Piper SandlerBoost Price TargetOverweight ➝ Overweight$122.00 ➝ $126.00
Slide 15
Back to 14
Continue to 16
 

More From MarketBeat
An AI run of epic proportions is only getting started
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
The 10 Best Lithium Stocks to Buy for a Post Gasoline World
Electric vehicles currently make up about 5% of new car sales in the United States. While they have received a...
MarketBeat
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...
Weiss Ratings | Sponsored
7 Food Stocks to Own for Under $20
Food is central to our daily lives and essential for maintaining our health and well-being. It is also criti...
MarketBeat
Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...
Paradigm Press | Sponsored
7 Defensive Stocks with Strong Growth Opportunities
Investors hate uncertainty. And when the markets get volatile (as they frequently do), volatile price action...
MarketBeat